The management of schizophrenia: focus on extended-release quetiapine fumarate

Joseph Peuskens Universitair Psychiatrisch Centrum KU Leuven, Campus St Jozef Kortenberg, Kortenberg, Belgium Abstract: Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Peuskens J
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://doaj.org/article/0a7a9e29149b401290c9eac1d3864aa3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0a7a9e29149b401290c9eac1d3864aa3
record_format dspace
spelling oai:doaj.org-article:0a7a9e29149b401290c9eac1d3864aa32021-12-02T08:19:25ZThe management of schizophrenia: focus on extended-release quetiapine fumarate1176-63281178-2021https://doaj.org/article/0a7a9e29149b401290c9eac1d3864aa32011-09-01T00:00:00Zhttp://www.dovepress.com/the-management-of-schizophrenia-focus-on-extended-release-quetiapine-f-a8324https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Joseph Peuskens Universitair Psychiatrisch Centrum KU Leuven, Campus St Jozef Kortenberg, Kortenberg, Belgium Abstract: Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity to further improve symptom control and long-term relapse prevention. Also, a number of factors, including tolerability and complex dosing regimens, can result in nonadherence to medication. Quetiapine is an atypical antipsychotic with proven efficacy and an established tolerability profile in schizophrenia. The once-daily extended-release formulation (quetiapine XR) offers a simplified dosing regimen and titration schedule. Short-term clinical studies have shown that quetiapine XR (400–800 mg/d) is efficacious in the acute treatment of schizophrenia, while a long-term study has shown that quetiapine XR was significantly more effective than placebo at preventing relapse. Furthermore, an investigation in which stable patients switched from the immediate-release formulation (quetiapine IR) to quetiapine XR showed that quetiapine XR is generally well tolerated and has no loss of efficacy compared with quetiapine IR. In patients who experienced insufficient efficacy or poor tolerability on their previous antipsychotic, switching to quetiapine XR significantly improved efficacy compared with the previous treatment. In conclusion, quetiapine XR is an effective and generally well tolerated treatment for schizophrenia. Furthermore, once-daily dosing may improve patient adherence, which may impact positively on patient outcomes. Keywords: adherence, atypical antipsychotics, adverse eventsPeuskens JDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 549-564 (2011)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Peuskens J
The management of schizophrenia: focus on extended-release quetiapine fumarate
description Joseph Peuskens Universitair Psychiatrisch Centrum KU Leuven, Campus St Jozef Kortenberg, Kortenberg, Belgium Abstract: Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity to further improve symptom control and long-term relapse prevention. Also, a number of factors, including tolerability and complex dosing regimens, can result in nonadherence to medication. Quetiapine is an atypical antipsychotic with proven efficacy and an established tolerability profile in schizophrenia. The once-daily extended-release formulation (quetiapine XR) offers a simplified dosing regimen and titration schedule. Short-term clinical studies have shown that quetiapine XR (400–800 mg/d) is efficacious in the acute treatment of schizophrenia, while a long-term study has shown that quetiapine XR was significantly more effective than placebo at preventing relapse. Furthermore, an investigation in which stable patients switched from the immediate-release formulation (quetiapine IR) to quetiapine XR showed that quetiapine XR is generally well tolerated and has no loss of efficacy compared with quetiapine IR. In patients who experienced insufficient efficacy or poor tolerability on their previous antipsychotic, switching to quetiapine XR significantly improved efficacy compared with the previous treatment. In conclusion, quetiapine XR is an effective and generally well tolerated treatment for schizophrenia. Furthermore, once-daily dosing may improve patient adherence, which may impact positively on patient outcomes. Keywords: adherence, atypical antipsychotics, adverse events
format article
author Peuskens J
author_facet Peuskens J
author_sort Peuskens J
title The management of schizophrenia: focus on extended-release quetiapine fumarate
title_short The management of schizophrenia: focus on extended-release quetiapine fumarate
title_full The management of schizophrenia: focus on extended-release quetiapine fumarate
title_fullStr The management of schizophrenia: focus on extended-release quetiapine fumarate
title_full_unstemmed The management of schizophrenia: focus on extended-release quetiapine fumarate
title_sort management of schizophrenia: focus on extended-release quetiapine fumarate
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/0a7a9e29149b401290c9eac1d3864aa3
work_keys_str_mv AT peuskensj themanagementofschizophreniafocusonextendedreleasequetiapinefumarate
AT peuskensj managementofschizophreniafocusonextendedreleasequetiapinefumarate
_version_ 1718398524795650048